Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Inhibitors Of Virion Release01:25

Inhibitors Of Virion Release

Viral replication and dissemination rely on efficient mechanisms for host cell entry, genome replication, assembly, and release. Influenza viruses, such as types A and B, are negative-sense single-stranded RNA viruses with a segmented genome, that depend on two critical surface glycoproteins to carry out these processes: hemagglutinin (HA) and neuraminidase (NA). HA initiates infection by binding to sialic acid residues on the surface of host epithelial cells, facilitating receptor-mediated...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Beyond the protocol: adherence to ECPR selection criteria and outcomes after Out-of-Hospital Cardiac Arrest (OHCA)-insights from the German Cardiac Arrest Registry (G-CAR).

Clinical research in cardiology : official journal of the German Cardiac Society·2026
Same author

Comparative analysis of cryoballoon versus radiofrequency catheter ablation in atrial fibrillation patients with impaired left ventricular ejection fraction.

International journal of cardiology. Heart & vasculature·2025
Same author

Community-based analysis of stroke prevention and effect of public interventions in atrial fibrillation: results from the ARENA project.

Clinical research in cardiology : official journal of the German Cardiac Society·2024
Same author

Work-Related Dermatoses of the Feet in Professional Dancers: A Pilot Study.

Medical problems of performing artists·2023
Same author

EU-CaRE study: Could exercise-based cardiac telerehabilitation also be cost-effective in elderly?

International journal of cardiology·2021
Same author

Patrolling the boundaries of social domains: Neural activations to violations of expectations for romantic and work relationships.

Social neuroscience·2021

Related Experiment Video

Updated: Jun 19, 2026

Engineering Antiviral Agents via Surface Plasmon Resonance
13:00

Engineering Antiviral Agents via Surface Plasmon Resonance

Published on: June 14, 2022

Glycoprotein IIb/IIIa antagonists: new developments.

U Zeymer1, R Zahn

  • 1Herzzentrum Ludwigshafen und Institut für Herzinfarktforschung Ludwigshafen an der Universität Heidelberg, Germany. Uwe.Zeymer@t-online.de

Hamostaseologie
|November 3, 2009
PubMed
Summary

Glycoprotein IIb/IIIa antagonists are beneficial for troponin-positive patients with non-ST-elevation acute coronary syndromes (NSTE-ACS) undergoing percutaneous coronary intervention (PCI). Optimal timing for these agents is post-angiography, not as upstream therapy, to avoid increased bleeding risks.

More Related Videos

Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics (DCAF)
09:39

Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics (DCAF)

Published on: September 17, 2019

Characterizing Modulators of Protease-Activated Receptors with a Calcium Mobilization Assay Using a Plate Reader
07:13

Characterizing Modulators of Protease-Activated Receptors with a Calcium Mobilization Assay Using a Plate Reader

Published on: May 24, 2024

Related Experiment Videos

Last Updated: Jun 19, 2026

Engineering Antiviral Agents via Surface Plasmon Resonance
13:00

Engineering Antiviral Agents via Surface Plasmon Resonance

Published on: June 14, 2022

Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics (DCAF)
09:39

Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics (DCAF)

Published on: September 17, 2019

Characterizing Modulators of Protease-Activated Receptors with a Calcium Mobilization Assay Using a Plate Reader
07:13

Characterizing Modulators of Protease-Activated Receptors with a Calcium Mobilization Assay Using a Plate Reader

Published on: May 24, 2024

Area of Science:

  • Cardiology
  • Interventional Cardiology
  • Pharmacology

Background:

  • Glycoprotein (GP) IIb/IIIa antagonists are critical in managing acute coronary syndromes (ACS).
  • Their role in patients undergoing percutaneous coronary intervention (PCI) is well-established, but optimal timing and specific patient populations require further clarification.
  • Previous studies have yielded mixed results regarding upstream versus in-hospital administration.

Purpose of the Study:

  • To evaluate the efficacy and safety of GP IIb/IIIa antagonists in patients with ACS, particularly in relation to timing of administration.
  • To compare outcomes in troponin-positive versus troponin-negative patients with NSTE-ACS.
  • To assess the impact of GP IIb/IIIa antagonists in ST-elevation myocardial infarction (STEMI) patients undergoing primary PCI.

Main Methods:

  • Review of key clinical trials including ISAR-REACT 2, EARLY-ACS, and BRAVE 3.
  • Analysis of data on abciximab, eptifibatide, and tirofiban administration.
  • Focus on patient stratification based on troponin status and ACS type (NSTE-ACS, STEMI).

Main Results:

  • Abciximab improved outcomes in troponin-positive NSTE-ACS patients undergoing PCI when given after initial angiography.
  • Upstream eptifibatide in high-risk NSTE-ACS patients did not improve ischemic complications but increased bleeding.
  • Prehospital tirofiban showed improved myocardial reperfusion in STEMI patients undergoing primary PCI; however, abciximab did not improve outcomes in a similar setting.

Conclusions:

  • GP IIb/IIIa antagonists should be administered after initial angiography and PCI decision in troponin-positive NSTE-ACS patients.
  • Upstream use of these agents, especially in NSTE-ACS, is associated with increased bleeding without significant ischemic benefit.
  • No significant differences in efficacy were observed between abciximab, tirofiban, and eptifibatide in comparative trials.